However, recently developed molecular targeted therapies and immune checkpoint inhibitors have improved the survival of patients with corresponding gene mutations or a sufficiently high tumour proportion score (TPS) for programmed cell death ligand 1 (PD-L1) [4, 5]. The gene discussed is CD274; the disease is neoplasm.